Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 17;11(3):249.
doi: 10.3390/life11030249.

Self-Reported Real-World Safety and Reactogenicity of COVID-19 Vaccines: A Vaccine Recipient Survey

Alexander G Mathioudakis  1   2 , Murad Ghrew  3   4   5 , Andrew Ustianowski  5   6 , Shazaad Ahmad  7 , Ray Borrow  8 , Lida Pieretta Papavasileiou  9 , Dimitrios Petrakis  10 , Nawar Diar Bakerly  3   11
Affiliations

Self-Reported Real-World Safety and Reactogenicity of COVID-19 Vaccines: A Vaccine Recipient Survey

Alexander G Mathioudakis et al. Life (Basel). .

Abstract

An online survey was conducted to compare the safety, tolerability and reactogenicity of available COVID-19 vaccines in different recipient groups. This survey was launched in February 2021 and ran for 11 days. Recipients of a first COVID-19 vaccine dose ≥7 days prior to survey completion were eligible. The incidence and severity of vaccination side effects were assessed. The survey was completed by 2002 respondents of whom 26.6% had a prior COVID-19 infection. A prior COVID-19 infection was associated with an increased risk of any side effect (risk ratio 1.08, 95% confidence intervals (1.05-1.11)), fever (2.24 (1.86-2.70)), breathlessness (2.05 (1.28-3.29)), flu-like illness (1.78 (1.51-2.10)), fatigue (1.34 (1.20-1.49)) and local reactions (1.10 (1.06-1.15)). It was also associated with an increased risk of severe side effects leading to hospital care (1.56 (1.14-2.12)). While mRNA vaccines were associated with a higher incidence of any side effect (1.06 (1.01-1.11)) compared with viral vector-based vaccines, these were generally milder (p < 0.001), mostly local reactions. Importantly, mRNA vaccine recipients reported a considerably lower incidence of systemic reactions (RR < 0.6) including anaphylaxis, swelling, flu-like illness, breathlessness and fatigue and of side effects requiring hospital care (0.42 (0.31-0.58)). Our study confirms the findings of recent randomised controlled trials (RCTs) demonstrating that COVID-19 vaccines are generally safe with limited severe side effects. For the first time, our study links prior COVID-19 illness with an increased incidence of vaccination side effects and demonstrates that mRNA vaccines cause milder, less frequent systemic side effects but more local reactions.

Keywords: COVID-19; COVID-19 vaccine; Coronavirus Disease 2019; adverse events; reactogenicity; safety; tolerability.

PubMed Disclaimer

Conflict of interest statement

All authors have completed the ICMJE uniform disclosure form. None of the authors has any conflict of interest in relation to this work. A.G.M. reports grants from Boehringer Ingelheim outside the submitted work. R.B. reports contract research on behalf of Public Health England for GlaxoSmithKline, Pfizer and Sanofi Pasteur outside the submitted work. N.D.B. reports personal fees from TEVA Pharma, GSK, AstraZeneca, Boehringer Ingelheim and Chiesi Pharma outside the submitted work.

Figures

Figure A1
Figure A1
Age of the participants stratified by whether they had or did not have a previous COVID-19 infection.
Figure A2
Figure A2
Age of the participants stratified by the type of vaccine they received.
Figure 1
Figure 1
Incidence and severity of self-reported side effects after the first dose of the COVID-19 vaccine among participants who had or did not have a known prior COVID-19 infection. Risk ratios less than 1 favoured those that did not have a prior COVID-19 infection.
Figure 2
Figure 2
Incidence and severity of side effects after the first dose of (1) an mRNA or (2) a viral vector vaccine. Risk ratios less than 1 favoured the mRNA vaccine.
See this image and copyright information in PMC

References

    1. Woolf S.H., Chapman D.A., Lee J.H. COVID-19 as the Leading Cause of Death in the United States. JAMA. 2021;325:123–124. - PMC - PubMed
    1. Arnold D.T., Hamilton F.W., Milne A., Morley A.J., Viner J., Attwood M., Noel A., Gunning S., Hatrick J., Hamilton S., et al. Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: Results from a prospective UK cohort. Thorax. 2020;76:399–401. doi: 10.1136/thoraxjnl-2020-216086. - DOI - PMC - PubMed
    1. Tangcharoensathien V., Bassett M.T., Meng Q., Mills A. Are overwhelmed health systems an inevitable consequence of covid-19? Experiences from China, Thailand, and New York State. BMJ. 2021;372:n83. - PMC - PubMed
    1. Baden L.R., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R., Diemert D., Spector S.A., Rouphael N., Creech C.B., et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 2021;384:403–416. doi: 10.1056/NEJMoa2035389. - DOI - PMC - PubMed
    1. Ramasamy M.N., Minassian A.M., Ewer K.J., Flaxman A.L., Folegatti P.M., Owens D.R., Voysey M., Aley P.K., Angus B., Babbage G., et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): A single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021;396:1979–1993. doi: 10.1016/S0140-6736(20)32466-1. - DOI - PMC - PubMed

LinkOut - more resources